Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT.
Health Technol Assess
; 28(14): 1-101, 2024 Mar.
Article
in En
| MEDLINE
| ID: mdl-38512064
Neutropenic sepsis, or infection with a low white blood cell count, can occur following cancer treatment. Usually patients receive treatment with intravenous antibiotics (antibiotics delivered into a vein) for two or more days. Patients at low risk of complications from their infection may be able to have a shorter period of intravenous antibiotics benefitting both patients and the NHS. The trial compared whether changing from intravenous to oral antibiotics (antibiotics taken by mouth as tablets or liquid) 1224 hours after starting antibiotic treatment ('early switch') is as effective as usual care. Patients could take part if they had started intravenous antibiotics for low-risk neutropenic sepsis. Patients were randomly allocated to 'early switch' or to usual care. The main outcome measured was treatment failure. Treatment failure happened if fever persisted or recurred despite antibiotics, if patients needed to change antibiotics, if they needed to be re-admitted to hospital or needed to be admitted to intensive care within 14 days or died. We had originally intended that 628 patients would take part, but after review of the design of the study the number needed to take part was revised to 230. We were not able to complete the trial as planned as unfortunately only 129 patients took part. As the trial was smaller than expected we were not able to draw conclusions as to whether 'early switch' is no less effective than usual care. Our findings suggest that 'early switch' might result in a shorter time in hospital initially; however, treatment failure was more likely to occur, meaning some patients had to return to hospital for further antibiotics. There were no differences in side effects and no serious complications from treatment or treatment failure (such as intensive care admission or death) among the 65 patients in the 'early switch' group. Patients were satisfied with 'early switch'. Early switch may be a treatment option for some patients with low-risk neutropenic sepsis who would prefer a shorter duration of hospital admission but accept a risk of needing hospital re-admission.
Key words
AMBULATORY CARE; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; CIPROFLOXACIN; COSTBENEFIT ANALYSIS; DURATION OF THERAPY; FEBRILE NEUTROPENIA; GUIDELINE ADHERENCE; HEALTH RESOURCES; PATIENT PREFERENCE; PIPERACILLIN; PRAGMATIC CLINICAL TRIALS AS TOPIC; RISK FACTORS; SEPSIS; TAZOBACTAM DRUG COMBINATION; TREATMENT FAILURE
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Neoplasms
/
Neutropenia
Limits:
Humans
Language:
En
Journal:
Health Technol Assess
Journal subject:
PESQUISA EM SERVICOS DE SAUDE
/
TECNOLOGIA MEDICA
Year:
2024
Document type:
Article
Affiliation country:
Reino Unido
Country of publication:
Reino Unido